Novo Nordisk Takes The Plunge Into Alzheimer's With Phase III Semaglutide Trial

GLP-1 Agonist Linked To Inflammation Control

 
• By Andrew McConaghie

Analysis of cardiovascular studies show GLP-1 drugs are associated with a 53% reduced risk of developing Alzheimer’s disease.

Novo Nordisk
Novo Nordisk is making a calculated gamble on semaglutide working in Alzheimer's disease.

More from Business

More from Scrip